KCT0007948招募中未知
Ph2 study of Savolitinib and Durvalumab (MEDI4736) combination in advanced MET amplified gastric cancer(VIKTORY-2)
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1.Provision of fully informed consent prior to any study specific procedures.
- •2.Patients must be = 19 years of age
- •3.Body weight >30 kg
- •4.MET amplification by local NGS
- •5.Patients with gastric cancer (GC) who are in progressive stages and have progressed during or after 1st or 2nd chemotherapy treatment, regardless of whether they are IO contactless (naïve) or IO
- •6. There shall be at least one measurable lesion according to the modified RECIST 1.1 criteria.
- •7. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
- •8. ECOG performance status 0-1 with no deterioration between screening and the first dose of study treatment
- •9. Patients must have a life expectancy = 3 months from proposed first dose date
- •10. Patients must have had a washout period of 2 weeks for any prior therapy prior to the start ot study drug. The following intervals between the end of the prior treatment and first dose of study drug must be observed: = 4 weeks for radiotherapy (patients who receive palliative radiation for nontarget lesions need not have a 4 week washout period and can be enrolled if at least >=7 days); patients may receive a stable dose of bisphosphonates or denusomab as long as these were started at least 4 weeks prior to treatment; = 4 weeks for major surgery; = 7 days for minor surgical procedures; = 14 days (or 5 half lives whoever is longest) for any investigational product.
- •11. 11.Patients must have acceptable bone marrow, liver and renal function measured within 28 days prior to administration of study treatment as defined below:
- •?Haemoglobin =9.0 g/dL (within 2 weeks of registration transfusion permitted)
- •?Absolute neutrophil count (ANC) = 1.5 x 109/L
- •?Platelet count =100 x 109/L (within 2 weeks of registration transfusion permitted)
- •?Total bilirubin = 1.5 x institutional upper limit of normal (ULN)
- •?AST (SGOT)/ALT (SGPT) = 2.5 x institutional upper limit of normal unless liver metastases are present in which case it must be = 5x ULN
- •?Serum creatinine =1.5 x institutional ULN
- •?Glomerular filtration rate < 45 mL/min as assessed by standard methodology at the investigating centre
- •12.12.Female patients must be using highly effective contraception during clinical trials and for three months after permanent discontinuation of drug administration, and there should be evidence that they are not breastfeeding, that they are negative in pregnancy tests, or that they meet one of the following criteria in screening
- •13.Mandatory biopsy during the screening window prior to dosing and at progression (fresh frozen will be optionally if clinically feasible)
排除标准
- •1. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.
- •2. 2.Any previous treatment with MET inhibitors (prior exposure to anti-PD1/PDL1 allowed)
- •<> Patients who have received prior anti–PD-1, anti PD-L1 or anti CTLA-4:
- •a.Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy.
- •b.All AEs while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study.
- •c.Must not have experienced a =Grade 3 immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immunotherapy. NOTE: Patients with endocrine AE of =Grade 2 are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic.
- •d.Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of > 10 mg prednisone or equivalent per day.
- •3. Any gastrointestinal condition that would preclude adequate absorption of savolitinib including but not limited to inability to swallow oral medication, refractory nausea and vomiting, chronic gastrointestinal diseases or previous significant bowel resection, intestinal obstruction or CTCAE grade 3 or grade 4 upper GI bleeding within 4 weeks before the enrollment.
- •4.Active or prior documented autoimmune or inflammatory disorders (including IBD[e.g. Chohn's disease, ulcerative colitis or diverticulitis], SLE, sarcoidosis syndrome, tuberculosis, Wegener syndrome, myasthenia gravis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, history of primary immunodeficiency.
- •5.Known to have tested positive for human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies) or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).
- •6.Active hepatitis B (HBV surface antigen [HBsAg] positive) or active hepatitis C.
- •7. Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression. Note: Subjects previously treated for CNS metastases that are asymptomatic, radiographically and neurologically stable for at least 4 weeks and do not require corticosteroids (of any dose) for symptomatic management for at least 4 weeks prior to the first dose of treatment are not excluded.
- •8.Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for =3 years.
- •9.Current or prior use of immunosuppressive medication within 4 weeks prior to the first dose of durvalumab, with the exceptions of intranasal, topical, and inhaled corticosteroids; systemic corticosteroids at physiologic doses not to exceed a dose > 10 mg prednisone / day or equivalent)
- •10.Patient was in receipt of any live attenuated vaccination within 30 days prior to study entry or within 30 days of receving study therapy
- •11.Patients currently receiving (or unable to stop use at least 2 weeks) prior to receiving the first dose of savolitinib, medications known t
研究者
相似试验
进行中（未招募）
1 期
A phase Ib/II study of Durvalumab (MEDI4736) combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)EUCTR2016-003998-17-BEGrand Hôpital de Charleroi57
招募中
2 期
Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)Stomach Cancer, AdenocarcinomaNCT05620628Jeeyun Lee25
招募中
不适用
Phase II, single-arm study of durvalumab (MEDI4736) and AZD 6738 combination therapy in relapsed small cell lung cancer SubjectsKCT0005058Samsung Medical Center45
进行中（未招募）
1 期
A study trying to find out if a combination of Durvalumab and Tremelimumab is more effective than doxorubicin in patients with advanced or metastatic soft tissue sarcoma.EUCTR2016-004750-15-DEAIO-Studien-gGmbH100
招募中
2 期
Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial)2024-515240-24-00Grupo Espanol Multidisciplinar En Cancer Digestivo60